Friday, April 07, 2017 3:20:51 PM
Discovery Harbour Resources Corp. has closed the non-brokered private placement, announced on March 24, 2017, of an unsecured convertible debenture in the principal amount of $100,000 with Richard Gilliam, a director and significant shareholder of the company. The debenture will be convertible, at the option of the holder, into common shares of the company on the following terms. The conversion price will be equal to the greater of five cents per share or the subscription price for each share in the most recently completed private placement of the company during the term of the debenture. The debenture matures 12 months from the date of the closing of the financing and bears no interest. Proceeds of the financing are anticipated to be used for general working capital.
All securities issued pursuant to the financing will be subject to a statutory hold period expiring four months and one day after closing of the financing. Mr. Gilliam is considered a related party within the meaning of Multilateral Instrument 61-101 -- protection of minority security holders in special transactions and the financing is therefore considered to be a related party transaction within the meaning of MI 61-101. The financing, however, is exempt from the valuation requirement of MI 61-101 by virtue of the exemption contained in Section 5.5(b) as the company's shares are not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(a) of MI 61-101 in that the fair market value of the consideration of the debenture issued to the related party did not exceed 25 per cent of the company's market capitalization. This news release is being filed less than 21 days before the closing of the financing because the company wishes to complete the financing in a timely manner.
Recent DHR News
- Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry • PR Newswire (US) • 05/03/2024 01:06:00 PM
- Danaher Reports First Quarter 2024 Results • PR Newswire (US) • 04/23/2024 10:00:00 AM
- Danaher Schedules First Quarter 2024 Earnings Conference Call • PR Newswire (US) • 03/21/2024 08:15:00 PM
- Danaher to Present at TD Cowen Health Care Conference • PR Newswire (US) • 02/27/2024 09:15:00 PM
- Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets • PR Newswire (US) • 02/22/2024 09:15:00 PM
- Danaher Announces Quarterly Dividend • PR Newswire (US) • 02/21/2024 09:15:00 PM
- Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Danaher Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 01/30/2024 11:00:00 AM
- Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution • PR Newswire (US) • 01/09/2024 12:30:00 PM
- Danaher Says 4Q Adjusted. Revenue to Fall by Less Than Forecast • Dow Jones News • 01/08/2024 09:57:00 PM
- Danaher CEO to Comment on Financial Performance • PR Newswire (US) • 01/08/2024 09:15:00 PM
- Danaher to Present at J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/02/2024 10:00:00 PM
- Danaher Schedules Fourth Quarter 2023 Earnings Conference Call • PR Newswire (US) • 12/21/2023 09:30:00 PM
- Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase • GlobeNewswire Inc. • 12/13/2023 09:06:00 PM
- Danaher Completes Acquisition of Abcam • PR Newswire (US) • 12/06/2023 12:30:00 PM
- Danaher Cuts Quarterly Dividend to 24 Cents • Dow Jones News • 12/05/2023 10:14:00 PM
- Danaher Announces Quarterly Dividend • PR Newswire (US) • 12/05/2023 09:30:00 PM
- Danaher to Present at Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/21/2023 09:15:00 PM
- Danaher on Track for Largest Percent Increase in Almost a Year -- Data Talk • Dow Jones News • 11/21/2023 07:22:00 PM
- Danaher appoints Christopher Riley to Executive Vice President for Biotechnology • PR Newswire (US) • 10/31/2023 11:30:00 AM
- Danaher 3Q Earnings, Sales Decline but Beat Estimates • Dow Jones News • 10/24/2023 10:41:00 AM
- Danaher Reports Third Quarter 2023 Results • PR Newswire (US) • 10/24/2023 10:00:00 AM
- Keep An Eye Out: Pre-Market Movers And Analyst Recommendations • IH Market News • 10/17/2023 10:34:10 AM
- Danaher Corporation Completes Separation of Veralto Corporation • PR Newswire (US) • 09/30/2023 12:00:00 PM
- Veralto Set to Join S&P 500; Vestis to Join S&P MidCap 400; Others to Join S&P SmallCap 600 • PR Newswire (US) • 09/28/2023 10:17:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM